Castle Biosciences Inc (NASDAQ:CSTL) — Market Cap & Net Worth
Market Cap & Net Worth: Castle Biosciences Inc (CSTL)
Castle Biosciences Inc (NASDAQ:CSTL) has a market capitalization of $724.17 Million ($724.17 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10671 globally and #2645 in its home market, demonstrating a 4.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Castle Biosciences Inc's stock price $24.81 by its total outstanding shares 29188659 (29.19 Million). Analyse cash efficiency ratio of Castle Biosciences Inc to see how efficiently the company converts income to cash.
Castle Biosciences Inc Market Cap History: 2019 to 2026
Castle Biosciences Inc's market capitalization history from 2019 to 2026. Data shows growth from $1.00 Billion to $724.17 Million (2.21% CAGR).
Index Memberships
Castle Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.03% | #285 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1052 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.04% | #169 of 263 |
Weight: Castle Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Castle Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Castle Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.34x
Castle Biosciences Inc's market cap is 2.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
42.64x
Castle Biosciences Inc's market cap is 42.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.00 Billion | $51.87 Million | $5.28 Million | 19.34x | 190.11x |
| 2020 | $1.96 Billion | $62.65 Million | -$10.28 Million | 31.29x | N/A |
| 2021 | $1.25 Billion | $94.08 Million | -$31.29 Million | 13.30x | N/A |
| 2022 | $687.10 Million | $137.04 Million | -$67.14 Million | 5.01x | N/A |
| 2023 | $629.89 Million | $219.79 Million | -$57.47 Million | 2.87x | N/A |
| 2024 | $777.88 Million | $332.07 Million | $18.25 Million | 2.34x | 42.64x |
Competitor Companies of CSTL by Market Capitalization
Companies near Castle Biosciences Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Castle Biosciences Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Castle Biosciences Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Castle Biosciences Inc's market cap moved from $1.00 Billion to $ 724.17 Million, with a yearly change of 2.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $724.17 Million | -36.22% |
| 2025 | $1.14 Billion | +45.97% |
| 2024 | $777.88 Million | +23.49% |
| 2023 | $629.89 Million | -8.33% |
| 2022 | $687.10 Million | -45.09% |
| 2021 | $1.25 Billion | -36.16% |
| 2020 | $1.96 Billion | +95.37% |
| 2019 | $1.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Castle Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $724.17 Million USD |
| MoneyControl | $724.17 Million USD |
| MarketWatch | $724.17 Million USD |
| marketcap.company | $724.17 Million USD |
| Reuters | $724.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a r… Read more